CPX 351 manufacturers
- CPX-351
-
- $1270.00
-
2026-05-15
- CAS:1256639-86-7
- Purity: 99.76%
- Supply Ability: 10g
|
| | CPX 351 Basic information |
| Product Name: | CPX 351 | | Synonyms: | CPX 351;CPX351;CPX-351;Cytarabine/daunonubicin;Daunonubicin/cytarabine;Vyxeos;5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone | | CAS: | 1256639-86-7 | | MF: | | | MW: | 770.74 | | EINECS: | | | Product Categories: | | | Mol File: | 1256639-86-7.mol |  |
| | CPX 351 Chemical Properties |
| | CPX 351 Usage And Synthesis |
| Description | CPX-351 is a Liposomal-encapsulated combination of daunorubicin and cytarabine for the treatment of newly diagnosed tAML or AML with myelodysplasia-related changes (AML-MRCs). |
| | CPX 351 Preparation Products And Raw materials |
|